Pharming Group N.V. (PHARM.AS) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. PHARM.AS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 16.07% | 30.00% | Pass |
| Interest-bearing investments | 21.56% | 30.00% | Pass |
| Non-permissible income | 0.58% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.70% | 33.00% | Pass |
| Interest-bearing investments | 35.82% | 33.00% | Fail |
| Non-liquid assets | 55.82% | at least 20.00% | Pass |
| Non-permissible income | 0.58% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 35.82% | 33.33% | Fail |
| Accounts receivable | 44.18% | 33.33% | Fail |
| Non-permissible income | 0.58% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 35.82% | 33.33% | Fail |
| Accounts receivable | 44.18% | 50.00% | Pass |
| Non-permissible income | 0.58% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 14.52% | 33.00% | Pass |
| Cash + interest-bearing securities | 19.48% | 33.00% | Pass |
| Accounts receivable | 4.54% | 33.00% | Pass |
| Non-permissible income | 0.58% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.24% | 33.00% | Pass |
| Cash + interest-bearing securities | 20.45% | 49.00% | Pass |
| Accounts receivable | 4.77% | 49.00% | Pass |
| Non-permissible income | 0.58% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.24% | 33.33% | Pass |
| Cash + interest-bearing securities | 20.45% | 33.33% | Pass |
| Accounts receivable | 25.22% | 49.00% | Pass |
| Non-permissible income | 0.58% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 38.00 | NEUTRAL |
| Stochastic %K (14) | 4.91 | BUY |
| CCI (20) | -167.26 | BUY |
| Williams %R (14) | -95.09 | BUY |
| MACD (12,26,9) | 0.00 | BUY |
| ROC (10) | -5.42 | SELL |
| Momentum (10) | -0.05 | SELL |
| EMA (10) | 0.98 | SELL |
| SMA (10) | 0.98 | SELL |
| EMA (20) | 0.99 | SELL |
| SMA (20) | 0.99 | SELL |
| EMA (30) | 1.00 | SELL |
| SMA (30) | 0.98 | SELL |
| EMA (50) | 1.04 | SELL |
| SMA (50) | 1.06 | SELL |
| EMA (100) | 1.11 | SELL |
| SMA (100) | 1.12 | SELL |
| EMA (200) | 1.22 | SELL |
| SMA (200) | 1.28 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2025-12-31, figures in EUR.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
